USPTO Art Unit 1626 Prosecution Statistics

Art Unit Information

Art Unit: 1626
Group: 1620
Tech Center: 1600
Total Cases: 28,108
Last Active: August 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19312645CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITORAugust 2025January 2026Allow410NoNo
19312755CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITORAugust 2025January 2026Allow410NoNo
19312786CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITORAugust 2025January 2026Allow410NoNo
19313046CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITORAugust 2025February 2026Allow610NoNo
19313010CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITORAugust 2025February 2026Allow610NoNo
19312656CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITORAugust 2025December 2025Allow300NoNo
19279271Arterial Application of Low Dose Ethyl Alcohol Enables Blood-Brain Barrier (BBB) Transient OpeningJuly 2025December 2025Allow400YesNo
19274703RUXOLITINIB FORMULATION FOR REDUCTION OF ITCH IN ATOPIC DERMATITISJuly 2025December 2025Allow500YesNo
19247100CONJUGATES, THEIR COMPOSITIONS, AND THEIR RELATED METHODSJune 2025December 2025Allow500YesNo
19238613METHOD FOR FORMING AN N-SUBSTITUTED PYRROLE FROM A HEXADIONE WITH A JUICE CATALYSTJune 2025August 2025Allow210NoNo
19235996Carbon-14 Radioisotope-Labeled Flonicamid and Synthesis Method ThereofJune 2025October 2025Allow410NoNo
19236398PREPARATION OF PSILOCYBIN, DIFFERENT POLYMORPHIC FORMS, INTERMEDIATES, FORMULATIONS AND THEIR USEJune 2025November 2025Allow510YesNo
19225802NON-COVALENT MODIFIERS OF AKT1 AND USES THEREOFJune 2025December 2025Allow610YesNo
192159387-METHYL INDOLE ANALOGS AND DOSAGE FORMS CONTAINING THE SAMEMay 2025August 2025Allow310NoNo
19194136Cancer TreatmentApril 2025February 2026Allow921YesNo
19187874JUICE-BASED SYNTHETIC METHOD FOR PYRROLESApril 2025July 2025Allow310NoNo
19187847PYRROLE SYNTHESIS METHOD USING JUICE CATALYSTApril 2025July 2025Allow310NoNo
19187833GREEN SYNTHESIS METHOD FOR FORMING SUBSTITUTED PYRROLESApril 2025June 2025Allow200YesNo
19187339SYNTHESIS OF N-SUBSTITUTED PYRROLES BY GREEN CATALYSTApril 2025June 2025Allow200YesNo
19179235HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCERApril 2025December 2025Allow811NoNo
19178837Salts of Obicetrapib and Processes for their Manufacture and Intermediates ThereofApril 2025August 2025Allow400YesNo
19177721NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOFApril 2025September 2025Allow500YesNo
19072385POLQ INHIBITORSMarch 2025April 2025Allow200YesNo
19065860IP AND IP ANALOGS DOSAGE REGIMENS FOR THE TREATMENT OF ECTOPIC CALCIFICATIONSFebruary 2025December 2025Allow910YesNo
19063141NOVEL COMPOUNDSFebruary 2025May 2025Allow200YesNo
19058309Isoindol-sulfilimine compound and use as a sigma-2 receptor inhibitor thereofFebruary 2025May 2025Allow300NoNo
19042986MORPHOLINE-3-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASESJanuary 2025April 2025Allow300YesNo
19041219CCR5 INHIBITORJanuary 2025May 2025Allow310NoNo
19039174COMBINATION THERAPY FOR THE TREATMENT OF CANCERJanuary 2025September 2025Abandon810NoNo
19031233COMPOUND WITH a-GLUCOSIDASE INHIBITORY ACTIVITY AND APPLICATION THEREOFJanuary 2025July 2025Allow510NoNo
19020776CRYSTALLINE PHARMACEUTICALLY ACCEPTABLE SALT AND POLYMORPHIC FORM OF THE GLUTAMINYL CYCLASE INHIBITOR VAROGLUTAMSTATJanuary 2025March 2025Allow200YesNo
18994183METHODS FOR PREPARING L-6-HYDROXYTRYPTOPHAN (HTP) DERIVATIVE AND INTERMEDIATES THEREOFJanuary 2025March 2026Allow1400YesNo
19003381ORGANOSELENIUM BENZIMIDAZOLE COMPOUNDS FOR TREATING CANCERDecember 2024March 2025Allow200NoNo
19002491CompoundsDecember 2024May 2025Allow400YesNo
19001374Arterial Application of Low Dose Ethyl Alcohol Enables Blood-Brain Barrier (BBB) Transient OpeningDecember 2024April 2025Allow300YesNo
18989682PREPARATION OF PSILOCYBIN, DIFFERENT POLYMORPHIC FORMS, INTERMEDIATES, FORMULATIONS AND THEIR USEDecember 2024July 2025Allow720NoNo
18973849LEFLUTROZOLE COMPOSITIONS OF MATTER AND PROCESSES FOR PREPARATIONDecember 2024March 2025Allow300NoNo
18968441MIXED SEROTONIN 5-HT2A/2C RECEPTOR AGONISTS AND METHODS FOR TREATING PAIN AND DEPRESSIONDecember 2024March 2025Allow311NoNo
18868756C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCERNovember 2024April 2025Allow510YesNo
18865805COMBINATION OF ENDOCANNABINOID AND MTOR INHIBITORS IN THE TREATMENT OF NEUROENDOCRINE NEOPLASMSNovember 2024October 2025Allow1101NoNo
18865727N-ISOPROPYL TRYPTAMINES AND METHOD OF MAKING MONOALKYLATED AND DIALKYLATED TRYPTAMINE ANALOGSNovember 2024April 2025Allow500NoNo
18939592CYTOTOXIC TREATMENT OF CANCER CELLSNovember 2024January 2025Allow210NoNo
18931132LAYERED METAL-ORGANIC FRAMEWORK MATERIAL AND PREPARATION METHOD AND USE THEREOFOctober 2024December 2025Allow1311YesNo
18912278MIRDAMETINIB TREATMENTOctober 2024December 2025Abandon1420NoNo
18912218MIRDAMETINIB TREATMENTOctober 2024July 2025Allow910YesNo
18912367MIRDAMETINIB TREATMENTOctober 2024January 2026Abandon1520NoNo
18904487ROCAGLATE DERIVATIVES AND USES THEREOFOctober 2024February 2025Allow500YesNo
189034872-AMINOMETHYLIMIDAZOLE MIMICS OF NS4A AND THEIR EFFECT THEREOF ON HEPATITIS C VIRUS NS3 PROTEASEOctober 2024June 2025Allow911YesNo
18847298NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE THEREOFSeptember 2024September 2025Allow1210YesNo
18847377NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDSeptember 2024February 2026Abandon1711NoNo
18883472APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASESSeptember 2024November 2024Allow200NoNo
18843302TRIAZOLYL CROSS-LINKING AGENT AS WELL AS PREPARATION METHOD AND USE THEREOFSeptember 2024April 2025Allow801YesNo
18800581NK3 MODULATORS AND USES THEREOFAugust 2024November 2024Allow300YesNo
18799676METHOD FOR CONTACTING CANCER CELLS WITH ANTITUMOR AGENT AND APOPTOTIC INDUCERAugust 2024October 2024Allow210NoNo
18780132Aminopyrimidine Derivatives as Cyclin-Dependent Kinase InhibitorsJuly 2024January 2025Allow600YesNo
18772244CRYSTALLINE FORMS OF AN NK-1 ANTAGONISTJuly 2024October 2025Allow1510YesNo
18768367BENZOPYRIMIDINE COMPOUNDS AND USE THEREOFJuly 2024January 2025Allow710YesNo
18767494PREPARATION OF PSILOCYBIN, DIFFERENT POLYMORPHIC FORMS, INTERMEDIATES, FORMULATIONS AND THEIR USEJuly 2024December 2024Allow510YesNo
18764298BIO-BASED EPOXY CHAIN EXTENDER AND PREPARATION METHOD THEREOFJuly 2024January 2025Allow720NoNo
18764274LASOFOXIFENE TREATMENT OF BREAST CANCERJuly 2024May 2025Allow1010YesNo
18763262SALTS AND SOLID FORMS OF (S)-3-(4-((4-(MORPHOLINOMETHYL)BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAMEJuly 2024February 2025Allow800YesNo
18758102METHODS OF TREATING MOOD DISORDERSJune 2024October 2025Allow1510NoNo
18753212TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORSJune 2024July 2025Abandon1210NoNo
18748709TREATMENT OF COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIAJune 2024September 2025Abandon1501NoNo
187478131,2,4-Oxadiazole Derivatives as ImmunomodulatorsJune 2024February 2026Allow2010NoNo
18745664PARP INHIBITORS FOR TREATING CANCER AND ASTHMAJune 2024April 2025Allow1010YesNo
18743634HETEROARYL AZOLE COMPOUND AND PEST CONTROL AGENTJune 2024February 2025Allow800NoNo
18742840CRYSTALLINE FORMS OF COMPOSITIONS COMPRISING PSILOCIN AND PSILOCYBINJune 2024June 2025Allow1210NoNo
18741888Neuroplastogens and Non-Hallucinogenic Serotonin 5-HT2A Receptor ModulatorsJune 2024December 2024Allow610NoNo
18718991COMPOSITIONS AND METHODS FOR MAKING AND USING SMALL MOLECULES IN THE TREATMENT OF CANCERJune 2024March 2025Allow910YesNo
18738245METHOD FOR MANUFACTURING AROMATIC NITRILE COMPOUNDJune 2024March 2026Allow2110NoNo
18717094PSILOCYBIN DERIVATIVESJune 2024April 2025Allow1010NoNo
18679720FORMS OF ATICAPRANTMay 2024August 2024Allow200YesNo
18680473METHODS OF TREATING MOOD DISORDERSMay 2024December 2024Allow610NoNo
18731154CFTR REGULATORS AND METHODS OF USE THEREOFMay 2024April 2025Allow1000NoNo
18678114PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERSMay 2024March 2025Allow920NoNo
18714111CONJUGATES, THEIR COMPOSITIONS, AND THEIR RELATED METHODSMay 2024April 2025Allow1100YesNo
18672808PREPARATION OF OXINDOLE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORSMay 2024May 2025Allow1201YesNo
18672696PREPARATION OF PHENETHYLAMINES AND CATHINONES AND STEREOISOMERS THEREOF AND PRECURSORS THEREOFMay 2024January 2026Abandon2031NoNo
18671458SALTS OF AN FGFR INHIBITORMay 2024July 2025Allow1410YesNo
18671182PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORSMay 2024December 2024Allow600NoNo
18666109SALTS AND SOLID FORMS OF (R)-1-(5-METHOXY-1H-INDOL-1-YL)-N,N-DIMETHYLPROPAN-2-AMINEMay 2024March 2025Allow1000YesNo
18662345Crystalline Forms Of An Androgen Receptor ModulatorMay 2024June 2025Abandon1310NoNo
18660668Apoptosis Signal-Regulating Kinase 1 Inhibitors and Methods of Use ThereofMay 2024October 2025Allow1700YesNo
186613373-(2-(1,3-DIOXOISOINDOLIN-2-YL)ETHYL)-5-(2-HYDROXY-5-NITROBENZYLIDENE)THIAZOLIDINE-2,4-DIONE AS A POTENTIAL ANTITUMOR AND APOPTOTIC INDUCERMay 2024July 2024Allow200NoNo
18659338PROCESSES FOR THE PREPARATION OF 4-{8-AMINO-3-[(2S)-1-(BUT-2-YNOYL)-PYRROLIDIN-2-YL]IMIDAZO[1,5-a]-PYRAZIN-1-YL}N-(PYRIDIN-2-YL)-BENZAMIDEMay 2024July 2025Allow1401NoNo
18657122SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORSMay 2024July 2025Allow1410NoNo
18657052CRYSTALLINE FORMS AND SALT FORMS OF A KINASE INHIBITORMay 2024March 2026Allow2220YesNo
18656222NEUROPROTECTIVE COMPOSITIONS AND METHODS OF USING THE SAMEMay 2024February 2026Allow2111NoNo
18655194Chemokine CXCR4 Receptor Modulators and Uses Related TheretoMay 2024November 2025Allow1811NoNo
186502073-[(1H-PYRAZOL-R-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOFApril 2024July 2024Allow300YesNo
18649583METHOD FOR INHIBITING PROLIFERATION OF CANCER CELLSApril 2024April 2025Allow1110NoNo
18649785METHOD FOR INHIBITING PROLIFERATION OF CANCER CELLSApril 2024May 2025Allow1311YesNo
18647107Antiviral Heterocyclic CompoundsApril 2024August 2025Allow1611NoNo
18645837DIACYLGLYCEROL KINASE MODULATING COMPOUNDSApril 2024March 2026Abandon2220YesNo
18644754NOVEL BENZYLTRYPTAMINE COMPOUNDSApril 2024July 2025Abandon1510NoNo
18638989HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38April 2024April 2025Allow1210YesNo
18637425Salts of Obicetrapib and Processes for their Manufacture and Intermediates ThereofApril 2024May 2025Allow1300YesNo
18636763PROCESS FOR PREPARING 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES AND INTERMEDIATE COMPOUNDApril 2024July 2024Allow320YesNo
186369053-(3-(1,3-DIOXOISOINDOLIN-2-YL) PROPYL)-5-(4-FLUOROBENZYLIDENE) THIAZOLIDINE-2,4-DIONE AS A POTENTIAL ANTITUMOR AND APOPTOTIC INDUCERApril 2024July 2024Allow300NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1626.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
86
Examiner Affirmed
52
(60.5%)
Examiner Reversed
34
(39.5%)
Reversal Percentile
78.7%
Higher than average

What This Means

With a 39.5% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
873
Allowed After Appeal Filing
304
(34.8%)
Not Allowed After Appeal Filing
569
(65.2%)
Filing Benefit Percentile
62.8%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 34.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Art Unit 1626 - Prosecution Statistics Summary

Executive Summary

Art Unit 1626 is part of Group 1620 in Technology Center 1600. This art unit has examined 28,108 patent applications in our dataset, with an overall allowance rate of 74.7%. Applications typically reach final disposition in approximately 23 months.

Comparative Analysis

Art Unit 1626's allowance rate of 74.7% places it in the 43% percentile among all USPTO art units. This art unit has a below-average allowance rate compared to other art units.

Prosecution Patterns

Applications in Art Unit 1626 receive an average of 1.24 office actions before reaching final disposition (in the 9% percentile). The median prosecution time is 23 months (in the 86% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With fewer office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is shorter than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.